BioCentury
ARTICLE | Distillery Therapeutics

Endocrine/metabolic

January 16, 2019 5:10 PM UTC

Mouse studies suggest CRISPR-Cas9-based gene editing therapies targeting HAO1 could help treat primary hyperoxaluria type 1, which is caused by loss-of-function AGXT mutations and results in renal acc...